Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 15;43(4):505-511.
doi: 10.1515/hmbci-2021-0099. eCollection 2022 Dec 1.

Esketamine-A quick-acting novel antidepressant without the disadvantages of ketamine

Sheikh Shoib  1 , Madhulika Kotra  2 , Sana Javed  3 , Vinh-Son Nguyen  4 , Barikar C Malathesh  5
Affiliations
Review

Esketamine-A quick-acting novel antidepressant without the disadvantages of ketamine

Sheikh Shoib et al. Horm Mol Biol Clin Investig. .

Abstract

Esketamine, which is an S-enantiomer of ketamine, is better than conventional antidepressants and even better than R-ketamine. This article discusses the mechanism of action of Esketamine, how different it is from other antidepressants, its side effect profile, indications for use, various routes of administration and the review of existing literature on Esketamine.

Keywords: antidepressant; esketamine; ketamine; major depressive disorder.

PubMed Disclaimer

References

    1. Bahr, R, Lopez, A, Rey, JA. Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant. P T 2019;44:340–75.
    1. Murrough, JW. Ketamine for depression: an update. Biol Psychiatr 2016;80:416–8. https://doi.org/10.1016/j.biopsych.2016.07.005.
    1. Molero, P, Ramos-Quiroga, JA, Martin-Santos, R, Calvo-Sánchez, E, Gutiérrez-Rojas, L, Meana, JJ. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs 2018;32:411–20. https://doi.org/10.1007/s40263-018-0519-3.
    1. Turner, EH. Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatr 2019;6:977–9. https://doi.org/10.1016/s2215-0366(19)30394-3.
    1. Salahudeen, MS, Wright, CM, Peterson, GM. Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Ther Adv Drug Saf 2020;11:2042098620937899. https://doi.org/10.1177/2042098620937899.

MeSH terms

LinkOut - more resources